Original paper
A phase 1 study on midostaurin plus panobinostat in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome
Abstract
Introduction: Midostaurin is a non-specific FLT3 inhibitor that showed anti-leukemic activity against both FLT3 mutated as well as unmutated Acute Myeloid Leukemia (AML) in early phase studies. Panobinostat, a potent oral pan-acetylase inhibitor had also shown significant anti-leukemic signals in early phase studies. In the preclinical study, our group had previously reported synergistic anti-leukemic activity when an FLT3 inhibitor was used in...
Paper Details
Title
A phase 1 study on midostaurin plus panobinostat in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome
Published Date
Jan 1, 2020
Journal
Volume
10
Issue
2
Pages
28 - 34
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History